CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 67 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02723396
NCT02723396N/ACompleted

Sleep & Move. Systematic Characterisation of Sleep Benefit in Parkinson's Disease. An Observational, Prospective Study

Neurocenter of Southern Switzerland·observational·Posted Mar 30, 2016·Updated Feb 13, 2024

In Brief

An observational study for Idiopathic Parkinson Disease. Completed, enrolled 67 participants across 1 site.

Detailed Summary

Sleep benefit (SB) is a prominent spontaneous, apparently unpredictable, transitory improvement in motor function reported by around 50% of patients affected by Parkinson's Disease (PD) after sleep and before taking their first dose of dopaminergic medications. This study aims at systematically characterizing SB in PD patients in an ecological setting and to explore the relationships between nocturnal and diurnal sleep and subjective and objective measures of motor function. A better understanding of this phenomenon is mandatory for future research on this topic.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSwitzerland

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 30, 2016
Enrollment StartMar 16, 2016
Primary CompletionMay 31, 2019
Study CompletionFeb 9, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 10.3 years ago